Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 5, 2010, Pages 490-498

  Mangoni, Arduino A ^a   Woodman, Richard J ^a   Gilbert, Andrew L ^b   Knights, Kathleen M ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

COX 2 inhibitors; Elderly; Non steroidal anti inflammatory drugs; Stroke

Indexed keywords

ANTIDIABETIC AGENT; ANTIOBESITY AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SALICYLIC ACID DERIVATIVE; SULINDAC; TIAPROFENIC ACID;

AGED; ARTICLE; AUSTRALIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ELDERLY CARE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VETERAN;

AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUSTRALIA; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MALE; PHARMACOEPIDEMIOLOGY; RETROSPECTIVE STUDIES; RISK; STROKE; VETERANS;

EID: 77952766162     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1945     Document Type: Article

References (42)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119(3): e21-e181.
2. Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008; 168(11): 1219-1224. (Pubitemid 351831405)
3. Roumie CL, Mitchel EF Jr, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39(7): 2037-2045.
4. Abraham NS, El Serag HB, Hartman C, Richardson P, Deswal A. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007; 25(8): 913-924. (Pubitemid 46525353)
5. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54(5): 1378-1389.
6. Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med 2007; 120(1): 98 e9-e16
7. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006; 37(7): 1725-1730. (Pubitemid 44297720)
8. Cullen DJ, Seager JM, Holmes S, et al. Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000; 14(2): 177-185. (Pubitemid 30088294)
9. Price-Forbes AN, Callaghan R, Allen ME, Rowe IF. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Rheumatology (Oxford) 2005; 44(7): 921-924.
10. Rossignol M, Abouelfath A, Lassalle R, et al. The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers. Br J Clin Pharmacol 2009; 67(1): 118-124.
11. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115(12): 1634-1642. (Pubitemid 46648649)
12. Choi NK, Park BJ, Jeong SW, Yu KH, Yoon BW. Nonaspirin non-steroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study. Stroke 2008; 39(3): 845-849.
13. Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006; 31(6): 565-576.
14. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332(7553): 1302-1308.
15. Bak S, Andersen M, Tsiropoulos I, et al. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke 2003; 34(2): 379-386.
16. Yamada Y, Metoki N, Yoshida H, et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke 2008; 39(8): 2211-2218.
17. Connor MD, Modi G,Warlow CP. Differences in the nature of stroke in a multiethnic urban South African population: the Johannesburg hospital stroke register. Stroke 2009; 40(2): 355-362.
18. Del Tacca M, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug: a review. Clin Drug Invest 2002; 22: 799-818. (Pubitemid 36005678)
19. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase- 2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96(13): 7563-7568.
20. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296(13): 1633-1644.
21. King G, Zeng L. Estimating risk and rate levels, ratios and differences in case-control studies. Stat Med 2002; 21(10): 1409-1427.
22. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann NY Acad Sci 1994; 714: 136-142.
23. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003; 65(2): 153-159.
24. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121(4): 289-300.
25. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs 1996; 51(2): 179-187.
26. Cheng HF, Harris RC. Does cyclooxygenase-2 affect blood pressure? Curr Hypertens Rep 2003; 5(1): 87-92.
27. Bowman TS, Gaziano JM, Kase CS, Sesso HD, Kurth T. Blood pressure measures and risk of total, ischemic, and hemorrhagic stroke in men. Neurology 2006; 67(5): 820-823.
28. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351(17): 1709-1711.
29. Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59(8): 1090-1096.
30. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59(12): 1690-1697.
31. McCullough PA, Li S, Jurkovitz CT, et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51 (4 Suppl 2): S38-S45.
32. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke 2003; 34(10): 2518-2532.
33. Greisenegger S, Zehetmayer S, Bauer P, et al. Polymorphisms in inflammatory genes and the risk of ischemic stroke and transient ischemic attack: results of a multilocus genotyping assay. Clin Chem 2009; 55(1): 134-138.
34. Nambi V, Hoogeveen RC, Chambless L, et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009; 40(2): 376-381.
35. Gallego J, Martinez VE, Munoz R. Patients at high risk for ischemic stroke: identification and actions. Cerebrovasc Dis 2007; 24 (Suppl 1): 49-63.
36. Jordan J, Segura T, Brea D, Galindo MF, Castillo J. Inflammation as therapeutic objective in stroke. Curr Pharm Des 2008; 14(33): 3549-3564.
37. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113(25): 2906-2913.
38. Rahme E, Watson DJ, Kong SX, Toubouti Y, Lelorier J. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2007; 16(5): 493-503.
39. Jick SS, Kaye JA, Jick H. Diclofenac and acute myocardial infarction in patients with no major risk factors. Br J Clin Pharmacol 2007; 64(5): 662-667.
40. van Staa TP, Rietbrock S, Setakis E, Leufkens HG. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 2008; 264(5): 481-492.
41. Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 2006; 29(7): 621-632.
42. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003; 146(4): 581-590.